U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Thyroid Gland Papillary Carcinoma

MedGen UID:
1712759
•Concept ID:
C5237306
•
Neoplastic Process

Definition

Thyroid gland papillary carcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Thyroid Gland Papillary Carcinoma

Professional guidelines

PubMed

Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.
Haddad R, Elisei R, Hoff AO, Liu Z, Pitoia F, Pruneri G, Sadow PM, Soares F, Turk A, Williams MD, Wirth LJ, Cabanillas ME
JAMA Oncol 2023 Aug 1;9(8):1132-1141. doi: 10.1001/jamaoncol.2023.1379. PMID: 37289450
Treatment of refractory thyroid cancer.
Berdelou A, Lamartina L, Klain M, Leboulleux S, Schlumberger M
Endocr Relat Cancer 2018 Apr;25(4):R209-R223. Epub 2018 Jan 25 doi: 10.1530/ERC-17-0542. PMID: 29371330
Differentiated Thyroid Cancer-Treatment: State of the Art.
Schmidbauer B, Menhart K, Hellwig D, Grosse J
Int J Mol Sci 2017 Jun 17;18(6) doi: 10.3390/ijms18061292. PMID: 28629126Free PMC Article

Recent clinical studies

Etiology

Aggressive Subtypes of Papillary Thyroid Carcinoma Smaller Than 1 cm.
Lee JS, Lee JS, Yun HJ, Kim SM, Chang H, Lee YS, Chang HS, Park CS
J Clin Endocrinol Metab 2023 May 17;108(6):1370-1375. doi: 10.1210/clinem/dgac739. PMID: 36546348Free PMC Article
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201
Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R, Fogarty CE, Ma B, Li H, Ni G, Liu X, Yuan J, Wang T
BMC Genomics 2021 Jul 27;22(1):576. doi: 10.1186/s12864-021-07895-6. PMID: 34315405Free PMC Article
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J
Lancet Oncol 2021 Aug;22(8):1126-1138. Epub 2021 Jul 5 doi: 10.1016/S1470-2045(21)00332-6. PMID: 34237250
Treatment of refractory thyroid cancer.
Berdelou A, Lamartina L, Klain M, Leboulleux S, Schlumberger M
Endocr Relat Cancer 2018 Apr;25(4):R209-R223. Epub 2018 Jan 25 doi: 10.1530/ERC-17-0542. PMID: 29371330

Diagnosis

Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.
Haddad R, Elisei R, Hoff AO, Liu Z, Pitoia F, Pruneri G, Sadow PM, Soares F, Turk A, Williams MD, Wirth LJ, Cabanillas ME
JAMA Oncol 2023 Aug 1;9(8):1132-1141. doi: 10.1001/jamaoncol.2023.1379. PMID: 37289450
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201
Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
Gosain R, Alexander JS, Gill A, Perez C
Curr Oncol Rep 2018 Sep 11;20(10):82. doi: 10.1007/s11912-018-0736-4. PMID: 30206719
Differentiated Thyroid Cancer-Treatment: State of the Art.
Schmidbauer B, Menhart K, Hellwig D, Grosse J
Int J Mol Sci 2017 Jun 17;18(6) doi: 10.3390/ijms18061292. PMID: 28629126Free PMC Article
Prognostic biomarkers in thyroid cancer.
Soares P, Celestino R, Melo M, Fonseca E, Sobrinho-Simões M
Virchows Arch 2014 Mar;464(3):333-46. Epub 2014 Feb 1 doi: 10.1007/s00428-013-1521-2. PMID: 24487783

Therapy

Radioiodine Refractory Differentiated Thyroid Cancer.
Chan WWL, Chan S, Kwong DLW
Methods Mol Biol 2022;2534:243-257. doi: 10.1007/978-1-0716-2505-7_17. PMID: 35670980
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J
Lancet Oncol 2021 Aug;22(8):1126-1138. Epub 2021 Jul 5 doi: 10.1016/S1470-2045(21)00332-6. PMID: 34237250
NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
Lee YA, Lee H, Im SW, Song YS, Oh DY, Kang HJ, Won JK, Jung KC, Kwon D, Chung EJ, Hah JH, Paeng JC, Kim JH, Choi J, Kim OH, Oh JM, Ahn BC, Wirth LJ, Shin CH, Kim JI, Park YJ
J Clin Invest 2021 Sep 15;131(18) doi: 10.1172/JCI144847. PMID: 34237031Free PMC Article
Differentiated Thyroid Cancer-Treatment: State of the Art.
Schmidbauer B, Menhart K, Hellwig D, Grosse J
Int J Mol Sci 2017 Jun 17;18(6) doi: 10.3390/ijms18061292. PMID: 28629126Free PMC Article

Prognosis

Radioiodine Refractory Differentiated Thyroid Cancer.
Chan WWL, Chan S, Kwong DLW
Methods Mol Biol 2022;2534:243-257. doi: 10.1007/978-1-0716-2505-7_17. PMID: 35670980
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201
Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma.
Pu W, Shi X, Yu P, Zhang M, Liu Z, Tan L, Han P, Wang Y, Ji D, Gan H, Wei W, Lu Z, Qu N, Hu J, Hu X, Luo Z, Li H, Ji Q, Wang J, Zhang X, Wang YL
Nat Commun 2021 Oct 18;12(1):6058. doi: 10.1038/s41467-021-26343-3. PMID: 34663816Free PMC Article
Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R, Fogarty CE, Ma B, Li H, Ni G, Liu X, Yuan J, Wang T
BMC Genomics 2021 Jul 27;22(1):576. doi: 10.1186/s12864-021-07895-6. PMID: 34315405Free PMC Article
Differentiated Thyroid Cancer-Treatment: State of the Art.
Schmidbauer B, Menhart K, Hellwig D, Grosse J
Int J Mol Sci 2017 Jun 17;18(6) doi: 10.3390/ijms18061292. PMID: 28629126Free PMC Article

Clinical prediction guides

Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.
Haddad R, Elisei R, Hoff AO, Liu Z, Pitoia F, Pruneri G, Sadow PM, Soares F, Turk A, Williams MD, Wirth LJ, Cabanillas ME
JAMA Oncol 2023 Aug 1;9(8):1132-1141. doi: 10.1001/jamaoncol.2023.1379. PMID: 37289450
Aggressive Subtypes of Papillary Thyroid Carcinoma Smaller Than 1 cm.
Lee JS, Lee JS, Yun HJ, Kim SM, Chang H, Lee YS, Chang HS, Park CS
J Clin Endocrinol Metab 2023 May 17;108(6):1370-1375. doi: 10.1210/clinem/dgac739. PMID: 36546348Free PMC Article
Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R, Fogarty CE, Ma B, Li H, Ni G, Liu X, Yuan J, Wang T
BMC Genomics 2021 Jul 27;22(1):576. doi: 10.1186/s12864-021-07895-6. PMID: 34315405Free PMC Article
Prognostic biomarkers in thyroid cancer.
Soares P, Celestino R, Melo M, Fonseca E, Sobrinho-Simões M
Virchows Arch 2014 Mar;464(3):333-46. Epub 2014 Feb 1 doi: 10.1007/s00428-013-1521-2. PMID: 24487783
Aggressive variants of papillary thyroid carcinoma.
Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A
Head Neck 2011 Jul;33(7):1052-9. Epub 2010 Sep 7 doi: 10.1002/hed.21494. PMID: 20824810

Recent systematic reviews

Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.
Yu J, Liu Z, Su Y, Peng X, Xie Y
Clin Endocrinol (Oxf) 2024 Apr;100(4):379-388. Epub 2024 Feb 13 doi: 10.1111/cen.15027. PMID: 38351437
Antineoplastic properties of polyphenols in TPC-1 human papillary thyroid carcinoma cell line: a systematic review.
Makiyama ML, Esposti MJPD, Siqueira MLR, Bagatini MD, de Oliveira Maciel SFV, Moreno M
Arch Endocrinol Metab 2023 Jun 19;67(6):e000645. doi: 10.20945/2359-3997000000645. PMID: 37364147Free PMC Article
Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials.
Su J, Wang M, Fu Y, Yan J, Shen Y, Jiang J, Wang J, Lu J, Zhong Y, Lin X, Lin Z, Lin S
Expert Rev Anticancer Ther 2022 Sep;22(9):999-1008. Epub 2022 Jul 20 doi: 10.1080/14737140.2022.2102000. PMID: 35833358
Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
Maghsoomi Z, Emami Z, Malboosbaf R, Malek M, Khamseh ME
BMC Cancer 2021 May 20;21(1):579. doi: 10.1186/s12885-021-08257-x. PMID: 34016077Free PMC Article
Differentiated Thyroid Cancer-Treatment: State of the Art.
Schmidbauer B, Menhart K, Hellwig D, Grosse J
Int J Mol Sci 2017 Jun 17;18(6) doi: 10.3390/ijms18061292. PMID: 28629126Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...